Advertisement

Topics

Immunomic Therapeutics (ITI) Company Profile

03:55 EDT 22nd September 2018 | BioPortfolio

Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company pioneering the study of the LAMP-based nucleic acid immunotherapy platforms. These investigational technologies have the potential to alter how we use immunotherapy for cancer, allergies and animal health. On the heels of two landmark deals in 2015, including an exclusive worldwide license with Astellas Pharma Inc. to explore the use of LAMP-Vax for use in the prevention and treatment of allergic diseases which resulted in over $350M in licensing revenue that year, the company has now focused on the application of LAMP technology in oncology. For information about ITI and LAMP Technology, visit www.immunomix.com.


News Articles [729 Associated News Articles listed on BioPortfolio]

Immunomic Therapeutics Senior Vice President of R&D to Participate in Bio+Tech Conference

Sr. VP of R&D will discuss lysosomal targeting technology as applied in cancer immunotherapy Tomorrow, Teri Heiland, Ph.D., Senior Vice President of Research and De...

Immunomic Therapeutics CEO to Present at Immuno-Oncology Summit

Presentation to Highlight the Challenges of Viral Targets in Cancer Tomorrow, Dr. Bill Hearl, Ph.D., Chief Executive Officer (CEO) of Immunomic Therapeutics, Inc. will present...

Immunomic CEO to Speak at 2018 BioHealth Capital Region Forum

Panel Will Discuss Strengths in BioHealth Immunotherapies Immunomic Therapeutics, Inc. (ITI) CEO Bill Hearl, Ph.D., will participate in a panel discussion on immunotherapy at ...

ITI Senior Director of Corporate Development to Participate in an All Women’s Leadership Panel Discussion and Dinner at ISPE’s First Women in Pharma Event

Immunomic Therapeutics, Inc. Senior Director of Corporate Development Sia Anagnostou will participate in ISPE’s first Women in Pharma Event in Gaithersburg, MD. The panel will c...

Immunomic Therapeutics to Present at the 2018 China BioMed Innovation and Investment Conference

Presentation to Highlight UNITE technology application to oncology Today, Sia Anagnostou, Head, China Corporate Development of Immunomic Therapeutics, Inc. (ITI) and Senior Sc...

Immunomic Therapeutics Appoints Recognized Immuno-Oncology Expert, Dr. Richard Ambinder, to its Scientific Advisory Board

Immunomic Therapeutics, Inc. (ITI), a privately held, Maryland-based biotechnology company, announced today that it has appointed immuno-oncology expert Richard Ambinder, M.D., Ph...

Proteostasis Therapeutics Announces Withdrawal of Equity Offering Due to Market Conditions

About Proteostasis Therapeutics, Inc. Proteostasis Therapeutics, Inc. is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis (CF) and other di...

Technical Perspectives on Biotech Stocks -- Adaptimmune Therapeutics, Akebia Therapeutics, ...

www.wallstequities.com/registration Adaptimmune Therapeutics Shares in Abingdon, the UK headquartered Adaptimmune Therapeutics PLC rose slightly by 0.41%, ending Wednesday's trading session at $12...

PubMed Articles [436 Associated PubMed Articles listed on BioPortfolio]

RNA Therapeutics (Almost) Comes of Age: Targeting, Delivery and Endosomal Escape.

Recent developments in intracellular protein delivery.

Protein therapeutics based on transcription factors, gene editing enzymes, signaling proteins and protein antigens, have the potential to provide cures for a wide number of untreatable diseases, but c...

RNA-targeted therapeutics for lipid disorders.

To summarize recent developments in the field of RNA-directed therapeutics targeting lipid disorders that are not effectively managed.

A Review of Therapeutics in Clinical Development for Respiratory Syncytial Virus and Influenza in Children.

Respiratory syncytial virus (RSV) and influenza are important viral pathogens worldwide. Children, in particular, bear considerable burdens of morbidity and mortality associated with these viruses. Th...

Pharmacokinetic Analysis of Intraocular Penetration of Latanoprost Solutions with Different Preservatives in Human Eyes.

Clinical Trials [154 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...

Companies [1256 Associated Companies listed on BioPortfolio]

Immunomic Therapeutics, Inc.(ITI)

Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company pioneering the study of the LAMP-based nucleic acid immunotherapy platforms. These inve...

Immunomic Therapeutics (ITI)

Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company pioneering the study of the LAMP-based nucleic acid immunotherapy platforms. These i...

Immunomic Therapeutics, Inc.

Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company headquartered in Hershey, PA with lab facilities in Rockville, MD. ITI is developing ne...

Immunomic Therapeutics, Inc. (ITI)

Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company headquartered in Hershey, PA with lab facilities in Rockville, MD. ITI is developing ne...

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

More Information about "Immunomic Therapeutics (ITI)" on BioPortfolio

We have published hundreds of Immunomic Therapeutics (ITI) news stories on BioPortfolio along with dozens of Immunomic Therapeutics (ITI) Clinical Trials and PubMed Articles about Immunomic Therapeutics (ITI) for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Immunomic Therapeutics (ITI) Companies in our database. You can also find out about relevant Immunomic Therapeutics (ITI) Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...


Corporate Database Quicklinks



Searches Linking to this Company Record